Emerging clinical evidence highlights three actionable principles for B-vitamin supplementation. First, before initiating B12, folate, or B6 therapy, comprehensive laboratory assessment of all three nutrients must occur—testing only one creates a false sense of adequacy. Second, high folate supplementation can paradoxically mask underlying B12 deficiency, particularly in older adults, delaying diagnosis of potentially irreversible neurological complications. Third, vitamin B6 supplementation above 100 mg daily carries documented risk for peripheral neuropathy, yet megadose formulations remain commercially available without appropriate clinical safeguards. These principles underscore a fundamental truth: biomarkers and individual biochemical context—not marketing messaging—must guide supplementation decisions. Clinicians should advocate for evidence-based dosing protocols tailored to patient-specific metabolic status rather than standardized, non-specific recommendations.
Was this article helpful?
